DE69329106T2 - Oxazolidinderivat und sein pharmazeutisch verträgliches salz - Google Patents

Oxazolidinderivat und sein pharmazeutisch verträgliches salz

Info

Publication number
DE69329106T2
DE69329106T2 DE69329106T DE69329106T DE69329106T2 DE 69329106 T2 DE69329106 T2 DE 69329106T2 DE 69329106 T DE69329106 T DE 69329106T DE 69329106 T DE69329106 T DE 69329106T DE 69329106 T2 DE69329106 T2 DE 69329106T2
Authority
DE
Germany
Prior art keywords
represent
alkyl
alkylene
optionally halogenated
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329106T
Other languages
English (en)
Other versions
DE69329106D1 (de
Inventor
Shingo Yano
Tomoyasu Ohno
Kazuo Ogawa
Haruo Yamada
Tetsuhiko Shirasaka
Hiroyuki Kawamura
Shinichi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69329106D1 publication Critical patent/DE69329106D1/de
Publication of DE69329106T2 publication Critical patent/DE69329106T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE69329106T 1992-04-30 1993-04-28 Oxazolidinderivat und sein pharmazeutisch verträgliches salz Expired - Fee Related DE69329106T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11177392 1992-04-30
PCT/JP1993/000559 WO1993022298A1 (en) 1992-04-30 1993-04-28 Oxazolidine derivative and pharmaceutically acceptable salt thereof

Publications (2)

Publication Number Publication Date
DE69329106D1 DE69329106D1 (de) 2000-08-31
DE69329106T2 true DE69329106T2 (de) 2001-03-22

Family

ID=14569807

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329106T Expired - Fee Related DE69329106T2 (de) 1992-04-30 1993-04-28 Oxazolidinderivat und sein pharmazeutisch verträgliches salz

Country Status (10)

Country Link
US (1) US5480899A (de)
EP (1) EP0605729B1 (de)
KR (1) KR0146931B1 (de)
AT (1) ATE194981T1 (de)
AU (1) AU653896B2 (de)
CA (1) CA2112129C (de)
DE (1) DE69329106T2 (de)
FI (1) FI935920A0 (de)
HU (2) HU220601B1 (de)
WO (1) WO1993022298A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653896B2 (en) * 1992-04-30 1994-10-13 Taiho Pharmaceutical Co., Ltd. Oxazolidine derivative and pharmaceutically acceptable salt thereof
DK1251127T3 (da) * 1992-12-23 2006-03-06 Bristol Myers Squibb Co Nye sidekædede-bærende taxaner og mellemprodukter deraf
TW268952B (de) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (de) * 1993-12-13 1996-09-21 Hoffmann La Roche
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
ATE170179T1 (de) * 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
ID30299A (id) 1998-06-05 2001-11-22 Astrazeneca Ab Turunan oksazolidinon, proses pembuatannya dan komposisi farmasi yang mengandungnya
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AU2006335108B2 (en) * 2005-12-30 2011-04-07 Merck Sharp & Dohme Corp. CETP inhibitors
JP5040036B2 (ja) 2005-12-30 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体
CA2678577A1 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
EP2141154A4 (de) 2007-03-30 2011-06-01 Inst Med Molecular Design Inc Oxazolidinonderivat mit hemmender wirkung auf die 11-hydroxysteroiddehydrogenase vom typ i
ES2395081T3 (es) * 2007-07-26 2013-02-08 Vitae Pharmaceuticals, Inc. Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
CA2712500A1 (en) * 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP2011510083A (ja) * 2008-01-24 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション ３，５−二置換−１，３−オキサゾリジン−２−オン誘導体
CA2714532A1 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
JP5730021B2 (ja) * 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
JP5538356B2 (ja) * 2008-03-18 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
JP5451752B2 (ja) * 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
RU2531272C2 (ru) 2008-05-01 2014-10-20 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
ES2432150T3 (es) 2008-07-25 2013-12-02 Boehringer Ingelheim International Gmbh Inhibidores cíclicos de la 11 beta-hidroxiesteroide deshidrogenasa 1
IES20090900A2 (en) * 2008-11-28 2010-07-07 Corden Pharma Ip Ltd Manufacture of beta blockers
EP2393807B1 (de) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Zyklische 11beta-hydroxysteroid-dehydrogenase-1-hemmer
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
EP2585444B1 (de) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanone als 11-beta-hsd1-hemmer zur behandlung von stoffwechselerkrankungen
EP2635268A1 (de) 2010-11-02 2013-09-11 Boehringer Ingelheim International GmbH Pharmazeutische kombinationen zur behandlung von stoffwechselerkrankungen
EP3445753A1 (de) * 2016-04-22 2019-02-27 Kat2Biz AB Difunktionelles pfropfmittel auf der basis von phenolischem rückgrat aus lignin
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2022075645A1 (ko) * 2020-10-08 2022-04-14 재단법인 대구경북첨단의료산업진흥재단 Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020262A (en) * 1957-12-19 1962-02-06 Jefferson Chem Co Inc Method for producing 2-oxazolidones from epoxides and isocyanates
DE3205457A1 (de) * 1982-02-16 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Oxazolidin-2-one
US4602093A (en) * 1984-02-08 1986-07-22 Merck & Co., Inc. Novel substituted imidazoles, their preparation and use
EP0394440B1 (de) * 1987-10-20 1994-05-11 Otsuka Pharmaceutical Co., Ltd. Phenylcarbonsäure-abkömmlinge
CA1330079C (en) * 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
EP0393607B1 (de) * 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarbonsäurederivate mit einem Heterocyclus
AU653896B2 (en) * 1992-04-30 1994-10-13 Taiho Pharmaceutical Co., Ltd. Oxazolidine derivative and pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
ATE194981T1 (de) 2000-08-15
EP0605729B1 (de) 2000-07-26
AU4271093A (en) 1993-11-29
HU211901A9 (en) 1996-01-29
KR940701389A (ko) 1994-05-28
WO1993022298A1 (en) 1993-11-11
HU220601B1 (hu) 2002-03-28
US5480899A (en) 1996-01-02
EP0605729A4 (en) 1994-08-24
KR0146931B1 (ko) 1998-08-17
AU653896B2 (en) 1994-10-13
HUT70423A (en) 1995-10-30
FI935920A (fi) 1993-12-29
DE69329106D1 (de) 2000-08-31
FI935920A0 (fi) 1993-12-29
EP0605729A1 (de) 1994-07-13
CA2112129A1 (en) 1993-11-11
CA2112129C (en) 1997-10-07

Similar Documents

Publication Publication Date Title
DE69329106D1 (de) Oxazolidinderivat und sein pharmazeutisch verträgliches salz
FI932445A0 (fi) Farmaceutiska foereningar
MA20770A1 (fr) Nouveaux acides quinolone-carboxyliques substitues a substituant diazabicycloalkyle ponte
KR890006603A (ko) 항균제로 유용한 아미노메틸 옥소옥사졸리디닐 에테닐벤젠 유도체
FI922141A (fi) Analogiamenetelmä uusien hypoglykeemisten oksatsolidiinidionien valmistamiseksi
ATE200286T1 (de) Chinolincarbonsäure-derivate
ES2121988T3 (es) Derivado de morfinano y uso medicinal.
PT94160A (pt) Processo para preparacao de derivados de alfa-aminocarboxamidas n-fenilalquil substituidas e composicoes farmaceuticas que os contem
DK426289A (da) Spiroforbindelser og farmaceutisk praeparat indeholdende en saadan forbindelse
ATE146473T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
DK0597107T3 (da) Lignananalog, fremstilling deraf og hypolipidæmisk medikament
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
ES2055077T3 (es) Un procedimiento para preparar derivados de amida de acido carboxilico.
BR9001734A (pt) Composto inseticida de diamino-etileno,processo para sua preparacao e composicao inseticida que o contem
ATE94879T1 (de) Makrolid-verbindungen.
MX9200777A (es) 4-[(2-benzotiazolil)metilamino]-alfa-[(3,4-difluorofenoxi)metil]-1-pip eridetanol.
BR8606203A (pt) Composto pesticida,processo para sua preparacao,composicao pesticida e processo para combater pragas de insetos
ATE171704T1 (de) Optisch wirksame alkylendioxybenzolderivate und ihre verwendung als arzneimittel
ES2059364T3 (es) Compuestos macrolidos.
NO924758L (no) Nye amidinoaftylfurankarboksylatderivater og syreaddisjonssalter derav
ES2037004T3 (es) Metodo para producir un compuesto relacionado con el antibiotico tan-749.
BR9200189A (pt) Composto de piridinossulfonamida substituida ou seu sal,processo para sua preparacao e herbicida que o contem
SE9201188L (sv) Ny användning
PT90506A (pt) Processo para a preparacao de compostos macrolidos
DE69011174D1 (de) Catecholaminester.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee